NL-OMON28727招募中不适用
Vasospastic angina treatment by Endothelin Receptor Antagonism; a proof of concept study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- AMC
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female patients = 18 and <75 years old;
- •Patients with a high frequency (>3 times per week) and duration of anginal complaints, presumed to be caused by VSA;
- •Absence of significant obstructive coronary artery disease (defined as stenosis > 50% in an epicardial coronary artery) documented by invasive coronary angiography;
- •Supporting evidence of myocardial ischemia or spasm, defined as either:
- •odocumented dynamic ECG abnormalities during an episode of angina, or
- •o(b) documented troponin rise during an episode of angina, or
- •o(c) documented coronary spasm during invasive coronary angiography with or without acetylcholine provocation testing;
- •Anginal complaints for at least 3 months despite optimal anti-anginal treatment, which is at the discretion of the treating cardiologist.
排除标准
- •Patients who are pregnant or nursing and those who plan pregnancy in the period up to 1 months after the study;
- •Women of childbearing potential not using contraception;
- •Patients with a limited life expectancy less than one year;
- •Patients unable to provide written informed consent, or are otherwise not suitable for inclusion according to the investigator.
- •Contraindication for macitentan
- •Patients with active liver disease or severe liver dysfunction with ASAT and/or ALAT >3x upper limit of normal (ULM);
- •Patients with known renal impairment (GFR<60 ml/min);
- •Patients with anemia;
- •Use of potent CYP3A4 inducers (rifampicin, St. John's wort, carbamazepine, phenytoin) due to reduced efficacy of macitentan.
- •Use of potent CYP3A4 inhibitors (itraconazole, ketoconazole, voriconazole, clarithromycin, ritonavir, saquinavir).
研究者
相似试验
已完成
4 期
Vasospastic angina treatment by Endothelin Receptor Antagonism; a proof of concept studyvasospastic angina pectorisvessel spasm of the coronary artery10011082NL-OMON55720Academisch Medisch Centrum30
进行中（未招募）
1 期
treatment with vasodilator of chest pain caused by spasm in the vessels of the heartVasospastic angina, i.e. epicardial vasospasm or microvascular coronary dysfunction.MedDRA version: 20.0Level: PTClassification code 10002383Term: Angina pectorisSystem Organ Class: 10007541 - Cardiac disordersEUCTR2018-002623-42-NLAcademic Medical Center30
进行中（未招募）
1 期
Short-term endothelin A receptor blockade in patients with on-pump coronary artery bypass grafting - BQ-123 in CABGaorto-coronary bypass surgery in patients with coronary artery diseaseMedDRA version: 12.1Level: LLTClassification code 10011077Term: Coronary artery bypassMedDRA version: 12.1Level: HLTClassification code 10011085Term: Ischaemic coronary artery disordersMedDRA version: 12.1Level: LLTClassification code 10011090Term: Coronary artery surgeryMedDRA version: 12.1Level: LLTClassification code 10011098Term: Coronary bypassMedDRA version: 12.1Level: LLTClassification code 10049887Term: Coronary revascularisationMedDRA version: 12.1Level: LLTClassification code 10054366Term: Coronary revascularizationEUCTR2010-023552-90-ATMedizinische Universität Wien, Abteilung für Herzchirurgie36
进行中（未招募）
不适用
Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension Randomisierte, placebokontrollierte, multizentrische, doppel- blinde Pilotstudie zur Untersuchung der Wirksamkeit, Sicherheit und Verträglichkeit von Bosentan bei der Behandlung von Pati-enten/innen mit diastolischer Herzinsuffizienz und sekundärer pulmonaler Hypertension (PH) - BADDHYMedDRA version: 9.1Level: LLTClassification code 10000158Term: Abnormal liver function testsHeart failure with normal left ventricle systolic function (HFNEF) are common causes of hospitalisation mainly in the elderly population and are frequently associated with pulmonary hypertension. It is commonly seen, that patients with left heart disease and pulmonary hypertension with right ventricle dysfunction have a worse prognosis. The medical condition to be investigated is HFNEF (Ejection fraction > 50%) and secondary pulmonary hypertension.MedDRA version: 9.1Level: LLTClassification code 10019171Term: Hb decreasedMedDRA version: 9.1Level: LLTClassification code 10005890Term: Body fluid retentionMedDRA version: 9.1Level: LLTClassification code 10019211Term: HeadacheMedDRA version: 9.1Level: LLTClassification code 10040850Term: Skin flushedMedDRA version: 9.1Level: LLTClassification code 10024127Term: Leg edemaMedDRA version: 9.1Level: LLTClassification code 10014264Term: Edematous weight gainMedDRA version: 9.1Level: LLTClassification code 10017884Term: Gastrooesophageal refluxEUCTR2008-005514-40-ATniversitätslehrkrankenhaus Hall in Tirol
进行中（未招募）
不适用
IcatibaNt In Treatment of Idiopathic Angio Edema. - INITIAtEEUCTR2010-019037-10-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)